Filter by Category:

Consultant Spotlight: Janet Raleigh, RHIA, CTR

Janet Raleigh

Janet Raleigh, RHIA, CTR, has worked with Registry Partners, Incorporated since May 2009. She began her employment as a Project CTR and was promoted to Project Manager in April 2011.  Janet has worked on a variety of projects consisting of state report only and accredited cancer program projects and has experience with facilities seeking their initial CoC accreditation.   Janet is also a QC Manager.  Janet performs…

Posted on Mar. 12, 2015 in Consultant Spotlight

Will you be attending the 41st Annual NCRA Meeting?

  Are You On A Mission?  Registry Partners Incorporated Is! The National Cancer Registrars Association (NCRA) 41st Annual Meeting will be held in historic San Antonio, Texas May 20 -23 this year.  The official workshop begins on Thursday, May 21st and concludes on Saturday, May 23rd with pre and post optional workshops available.   The meeting offers a variety of oncology professionals such as Certified Tumor…

Posted on Mar. 10, 2015 in From Our Perspective

Q&A: Treatment Category

Q: How do you code BCG followed by a TURB for bladder cancer? A: Per FORDS bladder surgery codes: If immunotherapy is followed by surgery of the type coded 20-80 code that surgery instead and code the immunotherapy only as immunotherapy.   Surgery code = 27 and immunotherapy code = 01   Q: A breast cancer patient has a sentinel lymph node biopsy followed by a separate…

Posted on Mar. 7, 2015 in How Should I Code This?

“My facility is concerned with the CP3R data regarding a breast cancer patient receiving Chemotherapy + Herceptin now being coded as a single agent. Have you addressed this with the Commission on Cancer?”

As many of us are preparing for and completing our 1st quarter Cancer Committee meetings, RQRS and CP3R data will likely be presented for review and discussion. One particular measure, MAC for Breast, stands out due to the drug category coding change of  coding chemotherapy agent Herceptin as Biologic therapy/Immunotherapy.  Effective with cases diagnosed 1/1/20113 , patients who receive 1 chemotherapy agent + Herceptin will be…

Posted on Mar. 6, 2015 in From Our Perspective